[Combined single-day treatment in acute vulvovaginal candidosis].
The aim of this study is to investigate the effectiveness of single-day treatment with oral fluconazole and topical fenticonazole in acute vulvovaginal candidosis (VVC). Infection was proven by detection of yeast cells and pseudohyphae on microscopic examination of vaginal wet smears, by mycological cultures, as well as by the clinical symptoms. The study included 108 patients. Treatment consisted in 150 mg oral Fluconazole and 600 mg topical Fenticonazole. Clinical and mycological examinations were performed on days 0, 7 and 14. The causative yeast fungi were: Candida albicans (83.3%), C. glabrata (11.2%), C. krusei (5.5%). On days 7 and 14 clinical cure rates were found to be 61.5% and 90.7%, while mycological cure rates were 62% and 88.88%, respectively. The above therapeutic regimen was found to be 95.5% effective with C. albicans, 83.3% with C. glabrata and non effective with C. krusei. It is concluded that single-day treatment of acute VVC caused by C. albicans with 150 mg oral fluconazole and 600 mg topical fenticonazole is effective.
St
S
Kovachev
A
A
Nacheva
R
R
Vacheva-Dobrevska
N
N
Vasilev
D000284:Administration, Oral; D000287:Administration, Topical; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002175:Candida / Q000187:drug effects / Q000302:isolation & purification; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*
D000935:Antifungal Agents; D007093:Imidazoles; D015725:Fluconazole; C033486:fenticonazole